3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Brain Neoplasms
1
Interventions
Temozolomide
38
Radiotherapy
22
Radiosurgery
22
Radiation
11
Magnetic Resonance Spectroscopy
11
Irinotecan
11
Cyclophosphamide
11
Etoposide
10
Surgical Procedures, Operative
9
Erlotinib Hydrochloride
9
Carmustine
9
pembrolizumab
8
Filgrastim
8
Carboplatin
8
Bevacizumab
7
Vincristine
6
Sorafenib
6
O(6)-benzylguanine
6
Nivolumab
6
Flucytosine
6
Aminolevulinic Acid
6
temsirolimus
5
sargramostim
5
Vorinostat
5
Trastuzumab
5
Topotecan
5
Lomustine
5
Imatinib Mesylate
5
Granulocyte Colony-Stimulating Factor
5
Everolimus
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Brain Neoplasms
×
Oncolytic Virotherapy
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled